Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.43 |
| ▸ | NMT2 | O60551 | 5/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21541131 | 1.00 | NMT1 (0.43) | NMT1NMT2SLC6A5CTSLSIRT6 | |
| SCHEMBL24297018 | 0.85 | NMT1 (0.49) | NMT1NMT2SIRT6SIRT1TLR2 | |
| SCHEMBL21541320 | 0.83 | NMT1 (0.50) | NMT1NMT2SLC6A5SIRT6SIRT1 | |
| SCHEMBL20357606 | 0.80 | SLC6A5 (0.51) | NMT1NMT2SLC6A5SIRT6SIRT1 | |
| SCHEMBL27345758 | 0.79 | NMT1 (0.47) | NMT1NMT2SLC6A5CTSLSIRT6 | |
| SCHEMBL23314705 | 0.79 | NMT1 (0.50) | NMT1NMT2SLC6A5SIRT6SIRT1 | |
| SCHEMBL30634501 | 0.78 | SLC6A5 (0.53) | NMT1NMT2SLC6A5FOLH1 | |
| SCHEMBL7284768 | 0.78 | SIRT6 (0.46) | NMT1NMT2SLC6A5SIRT6SIRT1 | |
| SCHEMBL25026533 | 0.78 | NOD1 (0.41) | CTSLSIRT6SIRT1ROCK2PRKACA | |
| SCHEMBL21541319 | 0.78 | CA1 (0.44) | MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | INTOCELL INC. (KR) | 2021-07-20 | — | — | US | disclosed |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | INTOCELL INC. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | DDOST, B3GAT3, GALNT10 | NMT1 74/4885NMT2 103/4885SLC6A5 3295/4885 |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | DDOST, B3GAT3, GALNT10 | NMT1 74/4885NMT2 103/4885SLC6A5 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.